갑상선 수질암의 치료 결과
The Treatment Outcomes of Medullary Thyroid Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives The aim of this study was to evaluate the treatment outcomes of medullary thyroid carcinoma (MTC) by retrospective data analysis. Subjects and Method We conducted a retrospective chart review of 17 cases of pathologically proven MTC patients who were treated from 1998 to 2010 at the department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine. Results The mean tumor size was 2.32 cm (0.5-3.4 cm). Seventy-one percent of patients were diagnosed with advanced stage (III or IV) of MTC. We performed RET genetic screening in 8 of 17 patients. Hereditary MTC was found in 3 of 17 patients (18%) and sporadic MTC was found in 14 of 17 (82%). The preoperative assessment of basal serum calcitonin (CT) level was performed in 15 of 17 patents. Eleven patients had elevated basal calcitonin levels (＞13 pg/mL). After the operation for MTC, the serum CT levels were elevated in 7 patients. Overall 5-year survival rate was 94%. Normalization of serum calcitonin level was accomplished more frequently in the absence of extra thyroidal invasion (p=0.034), multifocal tumor (p=0.02). Conclusion The initial treatment of MTC is total thyroidectomy with central compartment neck dissection with or without lateral neck dissection. To detect recurrence or metastasis, regular checking of serum calcitonin is necessary. A better knowledge of prognostic factors could improve the management of MTC patients.
Abstract
Background and Objectives The aim of this study was to evaluate the treatment outcomes of medullary thyroid carcinoma (MTC) by retrospective data analysis. Subjects and Method We conducted a retrospective chart review of 17 cases of pathologically proven MTC patients who were treated from 1998 to 2010 at the department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine. Results The mean tumor size was 2.32 cm (0.5-3.4 cm). Seventy-one percent of patients were diagnosed with advanced stage (III or IV) of MTC. We performed RET genetic screening in 8 of 17 patients. Hereditary MTC was found in 3 of 17 patients (18%) and sporadic MTC was found in 14 of 17 (82%). The preoperative assessment of basal serum calcitonin (CT) level was performed in 15 of 17 patents. Eleven patients had elevated basal calcitonin levels (＞13 pg/mL). After the operation for MTC, the serum CT levels were elevated in 7 patients. Overall 5-year survival rate was 94%. Normalization of serum calcitonin level was accomplished more frequently in the absence of extra thyroidal invasion (p=0.034), multifocal tumor (p=0.02). Conclusion The initial treatment of MTC is total thyroidectomy with central compartment neck dissection with or without lateral neck dissection. To detect recurrence or metastasis, regular checking of serum calcitonin is necessary. A better knowledge of prognostic factors could improve the management of MTC patients.
참고문헌 (19)
- Pacini F, "Medullary thyroid carcinoma", Clin Oncol (R Coll Radiol), 22(6), pp.475~485 (2010)
- Machens A, "Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results", Eur J Endocrinol, 157(1), pp.85~93 (2007)
- Gimm O, "Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma", J Cancer Res Clin Oncol, 127(3), pp.156~165 (2001)
- Oh SK, "Medullary carcinoma of the thyroid", J Korean Surg Soc, 56(1), pp.49~58 (1999)
- Eng C, "The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis", JAMA, 276(19), pp.1575~1579 (1996)
- Sippel RS, "Current management of medullary thyroid cancer", Oncologist, 13(5), pp.539~547 (2008)
- Hirokawa M, "Observer variation of encapsulated follicular lesions of the thyroid gland", Am J Surg Pathol, 26(11), pp.1508~1514 (2002)
- Gharib H, "Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970", Mayo Clin Proc, 67(10), pp.934~940 (1992)
- Moley JF, "Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection", Ann Surg, 229(6), pp.880~888 (1999)
- Scollo C, "Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer", J Clin Endocrinol Metab, 88(5), pp.2070~2075 (2003)
- Machens A, "Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer", World J Surg, 31(10), pp.1960~1965 (2007)
- Cooper DS, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
- Chen H, "Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection", Ann Surg, 227(6), pp.887~895 (1998)
- Laure Giraudet A, "Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times", Eur J Endocrinol, 158(2), pp.239~246 (2008)
- Machens A, "Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level", J Clin Endocrinol Metab, 90(4), pp.2029~2034 (2005)
- Barbet J, "Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma", J Clin Endocrinol Metab, 90(11), pp.6077~6084 (2005)
- Kebebew E, "Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems", Cancer, 88(5), pp.1139~1148 (2000)
- Modigliani E, "Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients", Clin Endocrinol (Oxf), 48(3), pp.265~273 (1998), The GETC Study Group. Groupe d’éude des tumeurs àcalcitonine.
- Dralle H, "The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study", J Intern Med, 238(4), pp.357~361 (1995)